Filing Flows › Repligen (RGEN) › Q3 2026 › vs Q3 2025
Repligen (RGEN) Q3 2026 vs Q3 2025 (year over year)
Repligen's revenue rose $20.5M (+11%) from $189M in Q3 2025 to $209M in Q3 2026. The biggest changes: Product +$20.5M (+11%); Royalty and other revenue +$5K (+13%).
Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%, net loss $38.4M, operating cash flow $43.1M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 18.2% | 23.0% | -4.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $209M | $189M | $20.5M | +11% |
| Royalty and other revenue | $44K | $39K | $5K | +13% |
| Revenue | $209M | $189M | $20.5M | +11% |
| Other income, net | $2.7M | $287K | $2.5M | +854% |
| Net loss | $38.4M | −$14.9M | $53.3M | — |
| Costs & expenses | $250M | $189M | $61.4M | +32% |
| Operating costs | $239M | $172M | $66.9M | +39% |
| Income tax | $11.6M | $2.2M | $9.4M | +428% |
| Operating cash sources | $81.5M | $33.2M | $48.3M | +146% |
| Depreciation & amortization | $19.1M | $20.0M | −$885K | -4% |
| Share-based compensation | $9.4M | $9.0M | $382K | +4% |
| Working capital & other | $53.1M | $4.2M | $48.8M | 13× |
| Net loss absorbed | $38.4M | −$14.9M | $53.3M | — |
| Operating cash flow | $43.1M | $48.1M | −$5.0M | -10% |
| Free cash flow (OCF − capex) | $38.2M | $43.4M | −$5.2M | -12% |
| Capital expenditures | $4.9M | $4.7M | $246K | +5% |
Questions
How much did Repligen's revenue grow year over year in Q3 2026?
Repligen's revenue rose $20.5M (+11%) from $189M in Q3 2025 to $209M in Q3 2026.
What drove Repligen's revenue change in Q3 2026?
Product +$20.5M (+11%); Royalty and other revenue +$5K (+13%).